TSVT
Price:
$4.4
Market Cap:
$226.59M
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2021-11-03
Stock Exchange
NASDAQ
Ticker
TSVT
According to 2seventy bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.44. This represents a change of 492.24% compared to the average of -0.24 of the last 4 quarters.
The mean historical PE Ratio of 2seventy bio, Inc. over the last ten years is -1.56. The current -1.44 PE Ratio has changed 9.10% with respect to the historical average. Over the past ten years (40 quarters), TSVT's PE Ratio was at its highest in in the March 2020 quarter at 5.57. The PE Ratio was at its lowest in in the December 2022 quarter at -3.92.
Average
-1.56
Median
-1.46
Minimum
-2.32
Maximum
-0.97
Discovering the peaks and valleys of 2seventy bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 134.02%
Maximum Annual PE Ratio = -0.97
Minimum Annual Increase = -39.96%
Minimum Annual PE Ratio = -2.32
Year | PE Ratio | Change |
---|---|---|
2023 | -0.97 | -26.40% |
2022 | -1.31 | -39.96% |
2021 | -2.19 | -5.70% |
2020 | -2.32 | 134.02% |
2019 | -0.99 | -38.22% |
The current PE Ratio of 2seventy bio, Inc. (TSVT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.49
5-year avg
-1.56
10-year avg
-1.56
2seventy bio, Inc.’s PE Ratio is greater than Intercept Pharmaceuticals, Inc. (-13.55), less than Puma Biotechnology, Inc. (12.46), greater than Iovance Biotherapeutics, Inc. (-6.48), less than Sarepta Therapeutics, Inc. (257.91), greater than Day One Biopharmaceuticals, Inc. (-7.39), greater than Inozyme Pharma, Inc. (-3.48), less than Zentalis Pharmaceuticals, Inc. (-1.08), greater than Syndax Pharmaceuticals, Inc. (-6.17), less than Protagonist Therapeutics, Inc. (14.97), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Cullinan Oncology, Inc. (-6.96), greater than Mersana Therapeutics, Inc. (-1.56), greater than Relay Therapeutics, Inc. (-2.57), greater than Arcus Biosciences, Inc. (-5.75), greater than Stoke Therapeutics, Inc. (-7.92), less than Kezar Life Sciences, Inc. (-0.41), greater than Phathom Pharmaceuticals, Inc. (-3.49), greater than Replimune Group, Inc. (-3.26), greater than Chinook Therapeutics, Inc. (-11.89), greater than DICE Therapeutics, Inc. (-23.17), greater than Pliant Therapeutics, Inc. (-4.19), greater than Crinetics Pharmaceuticals, Inc. (-15.40), greater than Ascendis Pharma A/S (-12.57),
Company | PE Ratio | Market cap |
---|---|---|
-13.55 | $794.69M | |
12.46 | $110.36M | |
-6.48 | $3.04B | |
257.91 | $12.29B | |
-7.39 | $1.25B | |
-3.48 | $312.42M | |
-1.08 | $210.48M | |
-6.17 | $1.63B | |
14.97 | $2.44B | |
-3.19 | $181.50M | |
-6.96 | $1.04B | |
-1.56 | $165.61M | |
-2.57 | $835.47M | |
-5.75 | $1.44B | |
-7.92 | $773.92M | |
-0.41 | $40.82M | |
-3.49 | $1.21B | |
-3.26 | $708.49M | |
-11.89 | $2.71B | |
-23.17 | $2.27B | |
-4.19 | $782.51M | |
-15.40 | $4.03B | |
-12.57 | $6.83B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 2seventy bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 2seventy bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is 2seventy bio, Inc.'s PE Ratio?
How is the PE Ratio calculated for 2seventy bio, Inc. (TSVT)?
What is the highest PE Ratio for 2seventy bio, Inc. (TSVT)?
What is the 3-year average PE Ratio for 2seventy bio, Inc. (TSVT)?
What is the 5-year average PE Ratio for 2seventy bio, Inc. (TSVT)?
How does the current PE Ratio for 2seventy bio, Inc. (TSVT) compare to its historical average?